Difference between revisions of "Carmustine wafer, polifeprosan 20 (Gliadel wafer)"
Warner-admin (talk | contribs) m (Text replacement - "Category:Nitrosureas" to "Category:Nitrosoureas") |
Warner-admin (talk | contribs) m (Text replacement - "manufacturer. Instead" to "manufacturer. Instead") |
||
Line 6: | Line 6: | ||
<br>Extravasation: n/a | <br>Extravasation: n/a | ||
− | For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. | + | For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as [http://www.thomsonhc.com/home/dispatch Micromedex], [http://online.lexi.com/ Lexicomp], [http://www.utdol.com/online/content/search.do UpToDate (courtesy of Lexicomp)], or the prescribing information.<ref name="insert"></ref> |
==Diseases for which it is used== | ==Diseases for which it is used== |
Revision as of 15:19, 3 December 2017
Also known as Gliadel wafer or polifeprosan 20 with carmustine implant.
General information
Class/mechanism: Biodegradable copolymer matrix (polifeprosan 20) embedded with carmustine, a nitrosourea which alkylates DNA and RNA and inhibits several key enzymatic processes by carbamoylation of amino acids in proteins. Each Gliadel wafer is 1.45 cm in diameter and 1 mm thick and contains 192.3 mg copolymer and 7.7 mg carmustine. Exposure to the surgical resection cavity results in hydrolyzation of anhydride bonds of the copolymer, which releases carmustine.[1][2][3]
Route: implanted wafer
Extravasation: n/a
For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as Micromedex, Lexicomp, UpToDate (courtesy of Lexicomp), or the prescribing information.[1]
Diseases for which it is used
Patient drug information
- Carmustine wafer, polifeprosan 20 (Gliadel) patient drug information (Chemocare)[4]
- Carmustine wafer, polifeprosan 20 (Gliadel) patient drug information (UpToDate)[5]
History of changes in FDA indication
- 9/23/1996: Inital FDA approval
References
- ↑ 1.0 1.1 Carmustine wafer, polifeprosan 20 (Gliadel) package insert
- ↑ Carmustine wafer, polifeprosan 20 (Gliadel) package insert (locally hosted backup)
- ↑ Gliadel manufacturer's website
- ↑ Carmustine wafer, polifeprosan 20 (Gliadel) patient drug information (Chemocare)
- ↑ Carmustine wafer, polifeprosan 20 (Gliadel) patient drug information (UpToDate)